Updated Nov. 17, 2023 10:54 am ET
There is a bit of cognitive dissonance in healthcare investing right now.
After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8